Objective: To increase the relapse-free survival rate of patients with locally advanced cancer of the oral cavity, tongue and pharynx using concurrent chemoradiоtherapy with dynamic accelerated hyperfractionation with concomitant boost.

Materials and methods. A randomized, prospective clinical trial included 280 men with diagnosis of squamous cell carcinoma of the oral cavity, tongue and pharynx III and IVA, B stages. All patients randomized to the main and control groups. In the main group, radiation therapy was performed by dynamic accelerated hyperfractionation with concomitant boost. In the control group, the conventional chemoradiotherapy used.

Results. For a comparative analysis of the development of loco-regional relapses and relapse-free survival, we included 172 patients with a complete tumor response. In the main group, recurrences of the primary tumor developed in 8 cases, in regional lymph nodes – in 7 cases. In the control group, local recurrences detected in 16 patients, regional – in 13, and locoregional – in 16 patients. Statistically significant differences (p < 0.001) of 5-year relapse-free survival rate of patients of the main (58.2%±6) and control (21.9%±6) groups were revealed.

The conclusion. The chemoradiоtherapy with dynamic accelerated hyperfractionation with concomitant boost is an effective option for treatment of patients with locally advanced head and neck cancer. The use of this option leads to a decrease in the number of loco-regional relapses and an increase in relapse-free survival.

1. IAEA-TECDOC-1588: Transition from 2-D Radiotherapy to 3-D Conformal and Intensity Modulated Radiotherapy / IAEA, VIENNA, 2008. – 61 р.

2. Overgaard J. Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials: A 30 year experience from the Danish head and neck group / JAMA, 2014. – S397, suppl.

3. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer / Beitler J. J. [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2014. – Vol. 89. – Р. 13–20.

4. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis / Lacas B. [et al.] // Lancet Oncol. – 2017. – Vol. 18. – Р. 1221–1237.

5. Bourhis J., Overgaard J., Audry H. et al. Hy-perfrac­tionated or accelerated radiotherapy in head and neck cancer: a meta-analysis / Lancet. – 2006. – Vol. 368. – Р. 843–854.

6. Overgaard J., Mohanti B. K., Begum N. et al. Five versus six fractions of radiotherapy per week for squamouscell carcinoma of the head and neck (IAEA-ACC study): a ran­domised, multicentre trial / Lancet Oncol. – 2010. – Vol. 11. Р. 553–560.

7. Lyhne N. M., Primdahl H., Kristensen C. A. et al. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma / Radiother Oncol. – 2015. – Vol. 117. Р. 91–98.